drugset / Trial / NCT01286051

Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles

NCT01286051

Completed 80 enrolled Houston Fertility Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

Ovulation induction (OI) using gonadotropins is one of the most widely prescribed treatments of infertility. One common problem encountered while attempting OI using gonadotropins is premature ovulation. The purpose of this study is to examine the effect of a single injection of a medication, called ganirelix, to prevent premature ovulation. Patients will be divided into two groups. In the first group, gonadotropins will be used to stimulate the ovaries. In the second group gonadotropins will be used in addition to a single injection of ganirelix, a gonadotropin releasing hormone (GnRH) antagonist. Pregnancy rates will be compared between groups.

Timeline

Start
2011-01
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganirelix Protein / enzyme biologic 250 ug Subcutaneous
Comparator Follitropin beta Protein / enzyme biologic 75 iu
Comparator Follitropin beta Protein / enzyme biologic 150 iu

Indications

No indication recorded.